ATE309997T1 - Entzündungshemmende benzimidazolverbindungen - Google Patents
Entzündungshemmende benzimidazolverbindungenInfo
- Publication number
- ATE309997T1 ATE309997T1 AT02716257T AT02716257T ATE309997T1 AT E309997 T1 ATE309997 T1 AT E309997T1 AT 02716257 T AT02716257 T AT 02716257T AT 02716257 T AT02716257 T AT 02716257T AT E309997 T1 ATE309997 T1 AT E309997T1
- Authority
- AT
- Austria
- Prior art keywords
- inflammatory
- benzimidazole compounds
- benzimidazole
- compounds
- inflammatory benzimidazole
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US27479101P | 2001-03-09 | 2001-03-09 | |
PCT/IB2002/000334 WO2002072576A1 (en) | 2001-03-09 | 2002-01-30 | Benzimidazole anti-inflammatory compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE309997T1 true ATE309997T1 (de) | 2005-12-15 |
Family
ID=23049627
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT02716257T ATE309997T1 (de) | 2001-03-09 | 2002-01-30 | Entzündungshemmende benzimidazolverbindungen |
Country Status (17)
Country | Link |
---|---|
US (1) | US7056918B2 (de) |
EP (1) | EP1370557B1 (de) |
JP (1) | JP2004526727A (de) |
AP (1) | AP2002002460A0 (de) |
AT (1) | ATE309997T1 (de) |
BR (1) | BR0207957A (de) |
CA (1) | CA2440211A1 (de) |
DE (1) | DE60207390T2 (de) |
DO (1) | DOP2002000349A (de) |
ES (1) | ES2251582T3 (de) |
GT (1) | GT200200043A (de) |
MX (1) | MXPA03008142A (de) |
PA (1) | PA8540901A1 (de) |
PE (1) | PE20030200A1 (de) |
TN (1) | TNSN02021A1 (de) |
UY (1) | UY27198A1 (de) |
WO (1) | WO2002072576A1 (de) |
Families Citing this family (89)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002088107A1 (en) * | 2001-04-26 | 2002-11-07 | Eisai Co., Ltd. | Nitrogenous fused-ring compound having pyrazolyl group as substituent and medicinal composition thereof |
WO2004014900A1 (en) * | 2002-08-09 | 2004-02-19 | Eli Lilly And Company | Benzimidazoles and benzothiazoles as inhibitors of map kinase |
CN101870691A (zh) | 2002-08-19 | 2010-10-27 | 劳洛斯治疗公司 | 2,4,5-三取代的咪唑及其作为抗菌剂的用途 |
US7012143B2 (en) | 2002-08-30 | 2006-03-14 | Dombroski Mark A | Cycloalkyl-[4-(difluorophenyl)-oxazol-5-yl]-triazolo-pyridines |
US6949652B2 (en) | 2002-08-30 | 2005-09-27 | Pfizer, Inc. | Crystalline forms of 3-isopropyl-6-[4-(2,5-difluoro-phenyl)-oxazol-5-yl]-[1,2,4]triazolo-[4,3-A]pyridine |
US7005523B2 (en) | 2002-08-30 | 2006-02-28 | Pfizer Inc. | Cycloalkyl-[4-(trifluorophenyl)-oxazol-5yl]-triazolo-pyridines |
PA8579601A1 (es) | 2002-08-30 | 2004-05-07 | Pfizer Prod Inc | Compuestos antiinflamatorios de di y trifloruro-triazolo-piridinas |
US7037923B2 (en) | 2002-08-30 | 2006-05-02 | Pfizer, Inc. | Alkyl-[4-(trifluorophenyl)-oxazol-5-yl]-triazolo-pyridines |
PL375980A1 (en) * | 2002-09-18 | 2005-12-12 | Pfizer Products Inc. | Novel imidazole compounds as transforming growth factor (tgf) inhibitors |
DE60330362D1 (de) | 2002-09-18 | 2010-01-14 | Pfizer Prod Inc | Neue pyrazol-verbindungen als hemmer des transformierenden wachstumsfaktors (tgf) |
JP2006517580A (ja) | 2003-02-14 | 2006-07-27 | ファイザー・プロダクツ・インク | 抗炎症化合物としてのトリアゾロピリジン |
PA8595001A1 (es) | 2003-03-04 | 2004-09-28 | Pfizer Prod Inc | Nuevos compuestos heteroaromaticos condensados que son inhibidores del factor de crecimiento transforante (tgf) |
DE10315569A1 (de) * | 2003-04-05 | 2004-10-14 | Merck Patent Gmbh | Substituierte Pyrazolverbindungen |
EP1654221A2 (de) * | 2003-06-10 | 2006-05-10 | Smithkline Beecham Corporation | Von anilin abgeleitete modulatoren von androgen-, glucocorticoid-, mineralcorticoid- und progesteronrezeptoren |
GB0313914D0 (en) * | 2003-06-16 | 2003-07-23 | Smithkline Beecham Corp | Compounds |
GB0313915D0 (en) * | 2003-06-16 | 2003-07-23 | Smithkline Beecham Corp | Compounds |
US7157471B2 (en) * | 2003-08-25 | 2007-01-02 | Boehringer Ingelheim International Gmbh | Haloalkyl- and piperidine-substituted benzimidazole-derivatives |
EP1692113B1 (de) | 2003-11-14 | 2017-09-27 | Lorus Therapeutics Inc. | Arylimidazole und deren verwendung als antikrebsmittel |
WO2005060967A1 (en) * | 2003-12-18 | 2005-07-07 | Pfizer Products Inc. | METHODS OF TREATING ACUTE INFLAMMATION IN ANIMALS WITH p38 MAP KINASE INHIBITORS |
WO2005080380A1 (en) * | 2004-02-03 | 2005-09-01 | Eli Lilly And Company | Kinase inhibitors |
US7569725B2 (en) * | 2004-10-21 | 2009-08-04 | Britsol-Myers Squibb Company | Anthranilic acid derivatives as inhibitors of 17β-hydroxysteroid dehydrogenase 3 |
JP4973191B2 (ja) * | 2004-11-10 | 2012-07-11 | 小野薬品工業株式会社 | 含窒素複素環化合物およびその医薬用途 |
TW200639163A (en) * | 2005-02-04 | 2006-11-16 | Genentech Inc | RAF inhibitor compounds and methods |
ES2473597T3 (es) | 2005-05-25 | 2014-07-07 | Lorus Therapeutics Inc. | Derivados de 2-indolil imidazo[4,5-d]fenantrolina y su uso en el tratamiento del cáncer |
WO2007015866A2 (en) * | 2005-07-20 | 2007-02-08 | Kalypsys, Inc. | Inhibitors of p38 kinase and methods of treating inflammatory disorders |
PE20070404A1 (es) * | 2005-07-29 | 2007-05-10 | Wyeth Corp | Compuestos derivados de cianopirrol-sulfonamida como moduladores del receptor de progesterona |
PE20070341A1 (es) * | 2005-07-29 | 2007-04-13 | Wyeth Corp | Derivados de pirrol como moduladores del receptor de progesterona |
PE20070182A1 (es) | 2005-07-29 | 2007-03-06 | Wyeth Corp | Derivados cianopirrol-fenil amida como moduladores del receptor de progesterona |
AU2006279794B2 (en) | 2005-08-12 | 2011-04-07 | Synta Pharmaceuticals Corp. | Pyrazole compounds that modulate HSP90 activity |
EP1829867A1 (de) * | 2006-03-03 | 2007-09-05 | Laboratorios Del Dr. Esteve, S.A. | Gegenüber dem Sigmarezeptor pharmazeutisch aktive Imidazolverbindungen |
CA2653217A1 (en) | 2006-05-25 | 2007-12-06 | Synta Pharmaceuticals Corp. | Method for treating proliferative disorders associated with protooncogene products |
ES2301380B1 (es) | 2006-08-09 | 2009-06-08 | Laboratorios Almirall S.A. | Nuevos derivados de 1,7-naftiridina. |
KR100832747B1 (ko) * | 2006-10-27 | 2008-05-27 | 한국화학연구원 | 아미노피라졸 유도체, 이의 제조 방법 및 이를 함유하는허혈성 질환의 예방 또는 치료용 조성물 |
ES2320955B1 (es) | 2007-03-02 | 2010-03-16 | Laboratorios Almirall S.A. | Nuevos derivados de 3-((1,2,4)triazolo(4,3-a)piridin-7-il)benzamida. |
ES2329639B1 (es) | 2007-04-26 | 2010-09-23 | Laboratorios Almirall S.A. | Nuevos derivados de 4,8-difenilpoliazanaftaleno. |
EP2108641A1 (de) | 2008-04-11 | 2009-10-14 | Laboratorios Almirall, S.A. | Neue substituierte Spiro[Cycloalkyl-1,3'-indo]-2'(1'H)-on-Derivate und ihre Verwendung als p38 mitogen-activated Kinase Inhibitoren |
EP2113503A1 (de) | 2008-04-28 | 2009-11-04 | Laboratorios Almirall, S.A. | Neue substituierte Indolin-2-on- Derivate und ihre Verwendung als p39 mitogen-activated Kinase Inhibitoren |
DE102008022221A1 (de) * | 2008-05-06 | 2009-11-12 | Universität des Saarlandes | Inhibitoren der humanen Aldosteronsynthase CYP11B2 |
TWI469979B (zh) * | 2008-12-24 | 2015-01-21 | Bial Portela & Ca Sa | 脂肪酸醯胺水解酶(faah)抑制劑、以及其藥學組成物與用途 |
EP2322176A1 (de) | 2009-11-11 | 2011-05-18 | Almirall, S.A. | Neue 7-Phenyl-[1,2,4]triazol[4,3-a]pyridin-3(2H)on-Derivate |
EP2560640A1 (de) | 2010-04-19 | 2013-02-27 | Synta Pharmaceuticals Corp. | Krebstherapie mit einer kombination aus hsp90-inhibitorverbindungen und einem egfr-hemmer |
US8993779B2 (en) | 2010-08-12 | 2015-03-31 | Merck Sharp & Dohme Corp. | Positive allosteric modulators of MGLUR2 |
RU2454235C2 (ru) * | 2010-10-11 | 2012-06-27 | Елена Сергеевна Кипарисова | Способ лечения пациентов с острой цереброваскулярной патологией на фоне посттравматического стрессового расстройства, выполняемый комбинированной психомедикаментозной терапией |
AR083868A1 (es) * | 2010-12-03 | 2013-03-27 | Lilly Co Eli | Compuestos de oxazol[5,4-b]piridin-5-ilo |
KR101316101B1 (ko) * | 2011-05-26 | 2013-10-11 | 연세대학교 산학협력단 | Ptk 6의 활성 억제용 조성물 및 이를 이용한 암 예방 및 치료용 조성물 |
UA114490C2 (uk) | 2011-10-06 | 2017-06-26 | Байєр Інтеллектуал Проперті Гмбх | Гетероциклілпіри(mі)динілпіразоли як фунгіциди |
EP2773345A1 (de) | 2011-11-02 | 2014-09-10 | Synta Pharmaceuticals Corp. | Krebstherapie unter verwendung einer kombination aus hsp90-inhibitoren mit topoisomerase-i-inhibitoren |
AU2012332424A1 (en) | 2011-11-02 | 2014-06-05 | Synta Pharmaceuticals Corp. | Combination therapy of Hsp90 inhibitors with platinum-containing agents |
US9402831B2 (en) | 2011-11-14 | 2016-08-02 | Synta Pharmaceutical Corp. | Combination therapy of HSP90 inhibitors with BRAF inhibitors |
JP6359008B2 (ja) * | 2012-06-11 | 2018-07-18 | ユーシービー バイオファルマ エスピーアールエル | Tnf−アルファ調節ベンゾイミダゾール |
US9765039B2 (en) | 2012-11-21 | 2017-09-19 | Zenith Epigenetics Ltd. | Biaryl derivatives as bromodomain inhibitors |
WO2014080290A2 (en) | 2012-11-21 | 2014-05-30 | Rvx Therapeutics Inc. | Cyclic amines as bromodomain inhibitors |
WO2014096965A2 (en) | 2012-12-21 | 2014-06-26 | Rvx Therapeutics Inc. | Novel heterocyclic compounds as bromodomain inhibitors |
US9309247B2 (en) | 2013-03-20 | 2016-04-12 | Lorus Therapeutics Inc. | 2-substituted imidazo[4,5-D]phenanthroline derivatives and their use in the treatment of cancer |
CA2902686C (en) | 2013-04-25 | 2017-01-24 | Beigene, Ltd. | Fused heterocyclic compounds as protein kinase inhibitors |
PL3010503T3 (pl) | 2013-06-21 | 2020-08-24 | Zenith Epigenetics Ltd. | Nowe bicykliczne inhibitory bromodomen |
WO2015004534A2 (en) | 2013-06-21 | 2015-01-15 | Zenith Epigenetics Corp. | Novel substituted bicyclic compounds as bromodomain inhibitors |
CN105593224B (zh) | 2013-07-31 | 2021-05-25 | 恒元生物医药科技(苏州)有限公司 | 作为溴结构域抑制剂的新型喹唑啉酮类化合物 |
PL3702373T3 (pl) | 2013-09-13 | 2022-12-05 | Beigene Switzerland Gmbh | Przeciwciała anty-PD1 i ich zastosowanie jako środki terapeutyczne i diagnostyczne |
JP6946000B2 (ja) | 2013-10-04 | 2021-10-06 | アプトース バイオサイエンシーズ, インコーポレイテッド | がんの治療用組成物及び方法 |
KR102130600B1 (ko) | 2014-07-03 | 2020-07-08 | 베이진 엘티디 | Pd-l1 항체와 이를 이용한 치료 및 진단 |
US10710992B2 (en) | 2014-12-01 | 2020-07-14 | Zenith Epigenetics Ltd. | Substituted pyridinones as bromodomain inhibitors |
CA2966303A1 (en) | 2014-12-01 | 2016-06-09 | Zenith Epigenetics Ltd. | Substituted pyridines as bromodomain inhibitors |
US10292968B2 (en) | 2014-12-11 | 2019-05-21 | Zenith Epigenetics Ltd. | Substituted heterocycles as bromodomain inhibitors |
CN107406438B (zh) | 2014-12-17 | 2021-05-14 | 恒翼生物医药科技(上海)有限公司 | 溴结构域的抑制剂 |
US9884868B2 (en) | 2015-03-02 | 2018-02-06 | Rigel Pharmaceuticals, Inc. | TGF-beta inhibitors |
US20190060286A1 (en) | 2016-02-29 | 2019-02-28 | University Of Florida Research Foundation, Incorpo | Chemotherapeutic Methods |
EP3481393B1 (de) | 2016-07-05 | 2021-04-14 | Beigene, Ltd. | Kombination eines pd-1-antagonisten und eines raf-inhibitors zur behandlung von krebs |
CA3033827A1 (en) | 2016-08-16 | 2018-02-22 | Beigene, Ltd. | Crystalline form of (s)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl )-4,5,6,7-tetra-hydropyrazolo[1,5-a]pyrimidine-3-carboxamide,preparation, and uses thereof |
CN110087680B (zh) | 2016-08-19 | 2024-03-19 | 百济神州有限公司 | 使用包含btk抑制剂的组合产品治疗癌症 |
CN109563051A (zh) * | 2016-08-22 | 2019-04-02 | 南京明德新药研发股份有限公司 | 作为pde4抑制剂的并环类化合物 |
WO2018137681A1 (en) | 2017-01-25 | 2018-08-02 | Beigene, Ltd. | Crystalline forms of (s) -7- (1- (but-2-ynoyl) piperidin-4-yl) -2- (4-phenoxyphenyl) -4, 5, 6, 7-tetrahy dropyrazolo [1, 5-a] pyrimidine-3-carboxamide, preparation, and uses thereof |
JP2020525411A (ja) | 2017-06-26 | 2020-08-27 | ベイジーン リミテッド | 肝細胞癌のための免疫療法 |
WO2019034009A1 (en) | 2017-08-12 | 2019-02-21 | Beigene, Ltd. | BTK INHIBITOR WITH ENHANCED DOUBLE SELECTIVITY |
EP3679027A1 (de) * | 2017-09-04 | 2020-07-15 | C4 Therapeutics, Inc. | Dihydrobenzimidazolone |
US10342786B2 (en) | 2017-10-05 | 2019-07-09 | Fulcrum Therapeutics, Inc. | P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD |
CN114732910A (zh) | 2017-10-05 | 2022-07-12 | 弗尔康医疗公司 | P38激酶抑制剂降低dux4和下游基因表达以用于治疗fshd |
CN111417395A (zh) | 2017-10-30 | 2020-07-14 | 艾普托斯生物科学公司 | 用于治疗癌症的芳基咪唑 |
WO2019089734A1 (en) * | 2017-10-31 | 2019-05-09 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Methods and compositions for the treatment of influenza |
WO2019108795A1 (en) | 2017-11-29 | 2019-06-06 | Beigene Switzerland Gmbh | Treatment of indolent or aggressive b-cell lymphomas using a combination comprising btk inhibitors |
CN109134431B (zh) * | 2018-10-10 | 2021-06-04 | 成都理工大学 | 作为囊性纤维化跨膜传导调节因子抑制剂的氨基咪唑偶联吡啶酮衍生物 |
EP3935050A4 (de) | 2019-03-06 | 2023-01-04 | C4 Therapeutics, Inc. | Heterocyclische verbindungen zur medizinischen behandlung |
EP3995490A4 (de) * | 2019-07-04 | 2023-08-09 | Medshine Discovery Inc. | Kristallform einer benzimidazol-2-on-verbindung, deren solvat, kristallform oder solvat davon und verfahren zu ihrer herstellung |
KR20220101137A (ko) | 2019-11-15 | 2022-07-19 | 길리애드 사이언시즈, 인코포레이티드 | Lpa 수용체 길항제로서의 트라이아졸 카르바메이트 피리딜 설폰아미드 및 이의 용도 |
JP2023529369A (ja) | 2020-06-03 | 2023-07-10 | ギリアード サイエンシーズ, インコーポレイテッド | Lpa受容体アンタゴニスト及びそれらの使用 |
CA3183097A1 (en) | 2020-06-03 | 2021-12-09 | Gilead Sciences, Inc. | Lpa receptor antagonists and uses thereof |
TWI818538B (zh) | 2021-05-11 | 2023-10-11 | 美商基利科學股份有限公司 | Lpa受體拮抗劑及其用途 |
US11939318B2 (en) | 2021-12-08 | 2024-03-26 | Gilead Sciences, Inc. | LPA receptor antagonists and uses thereof |
US11786531B1 (en) | 2022-06-08 | 2023-10-17 | Beigene Switzerland Gmbh | Methods of treating B-cell proliferative disorder |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SU667560A1 (ru) * | 1977-08-08 | 1979-06-15 | Тюменский государственный университет | Способ получени полиметилметакрилата |
US5716972A (en) | 1993-01-13 | 1998-02-10 | Smithkline Beecham Corporation | Pyridyl substituted imidazoles |
WO1995007922A1 (en) | 1993-09-17 | 1995-03-23 | Smithkline Beecham Corporation | Drug binding protein |
US5658903A (en) * | 1995-06-07 | 1997-08-19 | Smithkline Beecham Corporation | Imidazole compounds, compositions and use |
US5717100A (en) | 1995-10-06 | 1998-02-10 | Merck & Co., Inc. | Substituted imidazoles having anti-cancer and cytokine inhibitory activity |
ZA97175B (en) | 1996-01-11 | 1997-11-04 | Smithkline Beecham Corp | Novel substituted imidazole compounds. |
US5977103A (en) | 1996-01-11 | 1999-11-02 | Smithkline Beecham Corporation | Substituted imidazole compounds |
GB9713726D0 (en) | 1997-06-30 | 1997-09-03 | Ciba Geigy Ag | Organic compounds |
TW517055B (en) * | 1997-07-02 | 2003-01-11 | Smithkline Beecham Corp | Novel substituted imidazole compounds |
EP1082320A4 (de) | 1998-05-26 | 2001-11-21 | Smithkline Beecham Corp | Substituierte imidazolverbindungen |
US6207687B1 (en) * | 1998-07-31 | 2001-03-27 | Merck & Co., Inc. | Substituted imidazoles having cytokine inhibitory activity |
ATE266399T1 (de) * | 1998-08-20 | 2004-05-15 | Smithkline Beecham Corp | Neue substituierte triazolverbindungen |
US6350744B1 (en) | 1998-11-20 | 2002-02-26 | Merck & Co., Inc. | Compounds having cytokine inhibitory activity |
AU768259B2 (en) | 1998-12-16 | 2003-12-04 | Aventis Pharma Limited | Heteroaryl-cyclic acetals |
JP2002534385A (ja) | 1999-01-08 | 2002-10-15 | スミスクライン・ビーチャム・コーポレイション | 新規化合物 |
JP2002534468A (ja) | 1999-01-13 | 2002-10-15 | バイエル コーポレイション | p38キナーゼ阻害剤としてのω−カルボキシアリール置換ジフェニル尿素 |
CO5170501A1 (es) * | 1999-04-14 | 2002-06-27 | Novartis Ag | AZOLES SUSTITUIDOS UTILES PARA EL TRATAMIENTO DE ENFERMEDADES MEDIADAS POR TNFa eIL-1 Y ENFERMEDADES DEL METABOLISMO OSEO |
-
2002
- 2002-01-30 AP APAP/P/2002/002460A patent/AP2002002460A0/en unknown
- 2002-01-30 ES ES02716257T patent/ES2251582T3/es not_active Expired - Lifetime
- 2002-01-30 BR BR0207957-7A patent/BR0207957A/pt not_active IP Right Cessation
- 2002-01-30 AT AT02716257T patent/ATE309997T1/de not_active IP Right Cessation
- 2002-01-30 DE DE60207390T patent/DE60207390T2/de not_active Expired - Fee Related
- 2002-01-30 JP JP2002571492A patent/JP2004526727A/ja not_active Withdrawn
- 2002-01-30 CA CA002440211A patent/CA2440211A1/en not_active Abandoned
- 2002-01-30 MX MXPA03008142A patent/MXPA03008142A/es active IP Right Grant
- 2002-01-30 WO PCT/IB2002/000334 patent/WO2002072576A1/en active IP Right Grant
- 2002-01-30 EP EP02716257A patent/EP1370557B1/de not_active Expired - Lifetime
- 2002-02-28 DO DO2002000349A patent/DOP2002000349A/es unknown
- 2002-03-05 GT GT200200043A patent/GT200200043A/es unknown
- 2002-03-06 UY UY27198A patent/UY27198A1/es not_active Application Discontinuation
- 2002-03-06 PE PE2002000180A patent/PE20030200A1/es not_active Application Discontinuation
- 2002-03-08 TN TNTNSN02021A patent/TNSN02021A1/fr unknown
- 2002-03-08 PA PA20028540901A patent/PA8540901A1/es unknown
- 2002-03-11 US US10/094,717 patent/US7056918B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
MXPA03008142A (es) | 2003-12-12 |
ES2251582T3 (es) | 2006-05-01 |
CA2440211A1 (en) | 2002-09-19 |
TNSN02021A1 (fr) | 2005-12-23 |
UY27198A1 (es) | 2002-11-29 |
JP2004526727A (ja) | 2004-09-02 |
EP1370557B1 (de) | 2005-11-16 |
US7056918B2 (en) | 2006-06-06 |
PE20030200A1 (es) | 2003-03-12 |
DE60207390T2 (de) | 2006-07-20 |
PA8540901A1 (es) | 2002-10-28 |
GT200200043A (es) | 2003-02-11 |
BR0207957A (pt) | 2004-02-25 |
EP1370557A1 (de) | 2003-12-17 |
WO2002072576A1 (en) | 2002-09-19 |
AP2002002460A0 (en) | 2002-06-30 |
DOP2002000349A (es) | 2002-10-15 |
DE60207390D1 (de) | 2005-12-22 |
US20030092749A1 (en) | 2003-05-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE309997T1 (de) | Entzündungshemmende benzimidazolverbindungen | |
IS6971A (is) | Ný efnasambönd | |
NO20041339L (no) | Spiro-hydantoin-forbindelser anvendelige som anti-inflammatoriske midler | |
DE60227853D1 (de) | Substituierte Pyridinylamine | |
DK1358165T3 (da) | Imidazolderivater | |
DE50206892D1 (de) | Substituierte imidazotriazinone | |
DK1373228T3 (da) | Substituerede fluoralkoxyphenylsulfonylurinstoffer | |
DK1406858T3 (da) | Substituerede 4-aminocyklohexanoler | |
DE60216967D1 (de) | Substituierte cyclohexanderivate | |
SE0101239D0 (sv) | Pharmaceutically useful compounds | |
SE0103437D0 (sv) | New compounds | |
SE0100272D0 (sv) | New compounds | |
SE0103461D0 (sv) | New compounds | |
SE0102386D0 (sv) | New compounds | |
SE0102056D0 (sv) | New Compounds | |
SE0101958D0 (sv) | New compounds | |
SE0101660D0 (sv) | New compounds | |
SE0101659D0 (sv) | New compounds | |
SE0104366D0 (sv) | New compounds | |
SE0104342D0 (sv) | New compounds | |
SE0100629D0 (sv) | New compounds | |
SE0103700D0 (sv) | Uppsättning | |
FIU20010205U0 (fi) | Teline | |
SE0103802D0 (sv) | Novel compound | |
ITPG20010038A1 (it) | Stop psoriasi |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |